

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Reduction Act of 1995, no persons are required to respond to the Paperwork Reduction Reduc nation unless it contains a valid OMB control numb

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Examiner

Translation is attached

(Use as many sheets as necessary) of

Complete if Known Application Number 10/532,009 Filing Date October 22, 2003 (I.A.) First Named Inventor David S. Lawrence Art Unit To be assigned Examiner Name To be assigned Attorney Docket Number 96700/996

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	No.1	Document Number Number-Kind Code ² (f known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	1	^{US-} 5,635,608	06-03-1997	Haugland and Gee	
	2	^{US-} 6,258,603 B1	07-10-2001	Carlson et al.	
	3	^{US-} 6,514,722 B2	02-04-2003	Palsson et al.	
	4	US- 2002/0152493 A1	10-17-2002	Keith D. Allen	
	5	US- 2004/0023203 A1	02-05-2004	Miesenbock and Zemelman	
	6	US- 2004/0166553 A1	08-26-2004	Nguyen and McMaster	
	7	US- 5,399,346	03-21-2005	Anderson et al.	
	8	US- 6,242,188 B1	06-05-2001	Dattagupta et al.	
		US-			
	1	US-			

		FOREIGN	PATENT DOCU	MENTS		
Examiner Initiels*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevent Figures Appear	T ⁶
	9	WO 2004/018686 A1	03-04-2004	Cambridge et al.		
						Ш
	<u> </u>					ш
						ш
						ш

*EXAMINER: Initial if reference considered, whether or not citation is in conformance	
considered. Include copy of this form with next communication to applicant. Applica	int's unique citation designation number (optional). 2 See Kinds Codes of
USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that	issued the document, by the two-letter code (WIPO Standard ST.3). * For
Japanese patent documents, the indication of the year of the reign of the Emperor must	
the appropriate symbols as indicated on the document under WIPO Standard ST.16	if possible. Applicant is to place a check mark here if English language

Innestation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is distinated to bias 2 hours to complete to concluding gathering, preparing, and summitting the completed replication from the MESFTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this from and/or suggestions for the funding the standard of the control of the superior to complete this from and/or suggestions for the funding the standard of the control of the superior to complete this form and/or suggestions for the superior for the superior to the Chief Information Officer, U.S. Patent and Trademark Office. D. Box 1.98, Mexandria, N. 223-134. D. O. NOT SERES OR COMPLETED FORMS TO THIS ADDRESS. SENDING. TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO		t of 1995, no persons a	Compl te if Known			
Coosino				Applicati n Number	10/532,009		
INFO	DRMATION	N DIS	CLOSURE	Filing Dat	October 22, 2003 (I.A.)		
STATEMENT BY APPLICANT				First Named Inventor	David S. Lawrence		
l	(Use as many sh	oote ac o	occerand	Art Unit	To be assigned		
	(Oso es meny sn	iocia ea ii	ucessary)	Examiner Name	To be assigned		
Sheet	2	of	4	Attorney Docket Number	96700/996		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	10	ADAMS, S.R. and TSIEN, R.Y. (1993) "Controlling Cell Chemistry with Caged Compounds." Annu. Rev. Physiol. Vol. 55. pp 755-84.					
	11	ALBANESE, C. et al. (2002) "Recent advances in inducible expression in transgenic mice." Sem. in Cell & Develop. Biol. Vol. 13. pp 129-41.					
	12	ALBANESE, C. et al. (2000) "Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice." FASEB J. Vol. 14, pp 877-884.					
	13	ANDO, H. et al. (2001) "Photo-mediated gene activation using caged RNA/DNA in zebrafish embryos." Nature Genetics. Vol. 28. pp 317-25.					
	.14	ARAKAWA, H. et al. (2001) "Mutant loxP vectors for selectable marker recycle and conditional knock-outs." BMC Biotechnol. Vol. 1, No. 7, pp 1472-79.					
	15	BELSHAW, P.J. et al. (1996) "Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization." Chem. Biol. Vol. 3, No. 9. pp 731-38.					
•	16	CHEN, J.D. and EVANS, R.M. (1995) "A transcriptional co-repressor that interacts with nuclear hormone receptors." Nature Vol. 377, pp 454-57.					
	17	CRONIN, C.A. et al. (2001) "The lac operator-repressor system is functional in the mouse." Genes Dev. Vol. 15. pp 1506-17.					
	18	CRUZ, F.G. et al. (2000) "Light-Activated Gene Expression." J. Am. Chem. Soc. Vol. 122. pp 8777-78.					
	19	CURLEY, K. and LAWRENCE, D.S. (1999) "Light-activated proteins." Cur. Opin. Chem. Biol. Vol. 3. pp 84-88.					

Examiner	Date	
Signature	Considered	d

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicant is used only on elegiptation number (optional). 2 Applicant to place a check mark here if English Ingruspa Treatistion is attached.

This collection of normation is register by 37 CFR 1.83. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours public which is to file (and by the USFTO to process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours complete, including application, preprinting, and submitting the completed application from the full STOPT. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this comments of the amount of time you require to complete this comments of the amount of time you require to complete this comments of the amount of time you require to complete this comments on the amount of time you require to complete this comments on the amount of time you require to complete this comments on the amount of time you require to complete this comments on the amount of time you require to complete this comments on the amount of time you require to complete this comments on the amount of time you require to complete this comments of the amount of time you require to complete this comments of the amount of time you require to complete this comments of the amount of time you require to complete this comment of the your require to complete this comment of the your requirements of the process of the process of the your requirements of the process of the your requirements of the your r

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO	ducion A	A G. 1990, NO paradilo di	C required to respond to a condenie	on of information unless it contains a valid OMB control number. C mpl te if Known
Substitut	10 10 10 10 10 10			Applicati n Number	10/532,009
INFO	DRMATION	N DIS	CLOSURE	Filing Dat	October 22, 2003 (I.A.)
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	David S. Lawrence
	(Use as many sh	oote se n	ecordand	Art Unit	To be assigned
	(Cat as many an	outs as n	ecossary)	Examiner Name	To be assigned
Sheet	3	of	4	Attorney Docket Number	96700/996

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	20	DINAN, L. et al. (1999) "An extensive ecdysteroid CoMFA." J. Comput. Aided Mol. Des. Vol. 13. pp 185-207.					
	21	FEIL, R. et al. (1996) "Ligand-activated site-specific recombinaton in mice." Proc. Natl. Acad. Sci. USA. Vol. 93. pp 10887-90.					
	22	FISHER, G.H. et al. (1999) "Development of a flexible and specific gene delivery system for production of murine tumor models." Oncogene. Vol. 18. pp 5253-60.					
	23	FURUTA, T. et al. (1999) "Brominated 7-hydroxycoumarin-4-ylmethyls: Photolabile protecting groups with biologically useful cross-sections for two photon photolysis." Proc. Natl. Acad. Sci. USA. Vol. 96. pp. 1193-1200.					
	24	GINGRICH, J.R. and Roder, J. (1998) "Inducible Gene Expression in the Nervous System of Transgenic Mice." Annu. Rev. Neurosci. Vol. 21. pp 377-405.					
	25	MIKITANI, K. (1996) "A New Nonsteroidal Chemical Class of Ligand for the Ecdysteroid Receptor 3, 5-dl-Iert-buyl-4-hydroxy-N-isobutyl-benzamide Shows Apparent Insect Molling Hormone Activities at Molecular and Cellular Levels." Biochem. Biophys. Res. Comm. Vol. 227, p. 427-32.					
	26	MONROE, W.T. et al. (1999) " Targeting Expression with Light Using Caged DNA." J. Biol. Chem. Vol. 274. No. 30. pp 20895-20900.					
	27	NAGY, A. (2000) "Cre Recombinase: The Universal Reagent for Genome Tailoring." Genesis. Vol. 26, pp 99-109.					
	28	NO, D. et al. (1996) "Ecdysone-inducible gene expression in mammalian cells and transgenic mice." Proc Natl Acad Sci USA. Vol. 93. pp 3346-51.					
	29	ORSULIC, S. et al. (2002) "Induction of ovarian cancer by defined multiple genetic changes in a mouse model system." Cancer Cell. Vol.1. pp 53-62.					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

¹ Agolican's unique cluston designation number (coloras), 2 Agolican's to bytes a check mark here if English Inarquago Translation is attached.
This coloration of Information is required by 37 CFF 13.8. The information is required to obtain or relata to beath or yet byte with bit to file (and by the USPTO to process) an application. Confederatisty is governed by 35 U.S.C. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to compilet application from the USPTO. Them set vary depending upon the inflored cases. Any remmens on the application, program, and submitting the compileted application from the to USPTO. Them set vary depending upon the inflored cases. Any remmens on the Trademirk Office, P.O. Box 1450, Alexandrix, VA. 2213-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Sex 1450, Alexandrix, VA. 22213-1450, AV 22213-1450, VA 22213-1450,

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	ter the Paperwork Rec	fuction Ac	t of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number. Compl t if Known
Substitut	e lor torm 144sir-10			Applicati n Numb r	10/532,009
			CLOSURE	Filing Date	October 22, 2003 (I.A.)
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	David S. Lawrence
	(Use as many she	aate se n	acassand	Art Unit	To be assigned
İ	(Ose as many and	,013 63 //		Examiner Name	To be assigned
Sheet	4	of	4	Attorney Docket Number	96700/996

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	30	PAO, E. et al. (2003) "Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance." Proc. Natl. Acad. Sci. USA. Vol. 100. No. 15. pp 8764-69.					
	31	PETIT, D.L. et al. (1997) "Chemical Two-Photon Uncaging: a Novel Approach to Mapping Glutamate Receptors." Neuron. Vol. 19. pp 465-71.					
	32	RYDING, A.D.S. et al. (2001) "Conditional transgenic technologies." J. Endocrinol. Vol. 171. pp 1-14.					
	33	SAEZ, E. et al. (2000) "Identification of ligands and coligands for the ecdysone- regulated gene switch." Proc. Natl. Acad. Sci. USA. Vol. 97. No. 26. pp 14512-17.					
	34	SHOCKETT, P.E. and Schatz, D.G. (1996) "Diverse strategies for tetracycline-regulated inducible gene expression." Proc. Natl. Acad. Sci. USA. Vol. 93. pp 5173-76.					
	35	WANG, J. et al. (1998) "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by inleraction with the human N-CoR/mSin3/HDAC1 complex." Proc. Natl. Acad. Sci. USA. Vol. 95, pp. 10860-65.					

Examiner		Date	
Signature	/Jake Vu/	Considered	10/24/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

consistency include copy of not some winness, conformationation is appeared.

The collection of incomparison is a comparison to the conformation of the conformation is statistically and the conformation is required by 37 UFF 1.58. His information is required by 37 UFF 1.58. His information is required by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete depotation. The collection of information is required by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete depotation on the the USFTO. Time will very depotation to complete depotation on the the USFTO. Time will very depotation growth in complete depotation on the the USFTO. Time will very depotation growth in complete depotation from the third of the use o